

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mary M. Mader, et al.

Group Art Unit: 1626

Serial No.: 10/535,002

Examiner:
S. Young

Filing Date: November 13, 2003

US Nat'l Entry Date: May 12, 2005

Conf. No.: 9111

For: ANTITUMOR BENZOYLSULFONAMIDES

Docket No.: X-16114

RESPONSE TO FINAL RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

The present application entered the U.S. national phase, through the PCT, under 35 U.S.C. §371 on May 12, 2005. The present application was subjected to a restriction requirement under U.S.C. §121 and §372 on May 16, 2006. In order to be responsive, Applicants made an election, but traversed this rejection on June 16, 2006. The restriction requirement was made final with Applicants' election deemed allowable on July 14, 2006. Applicants filed a petition on August 2, 2006 to the Technology Center Director under 37 C.F.R. §1.144 for review and modification of the restriction requirement asserting that the restriction requirement was improper. The petition was granted on October 17, 2006 as it relates to Group VI, but denied for Groups I-V. Applicants submitted a supplemental petition on November 3, 2006 to the Director of Technology to request the Director to reconsider the denial of the petition as it relates to Groups I-V (and all remaining material). The petition decision, denying Groups I-V, was affirmed on January 4, 2007. Applicants still

maintain their traversal of the restriction for all the reasons of record, however, Applicants respectfully now submit the following amendments, having taken a three-month extension, to put the present application in condition for allowance, as per the material deemed allowable by the Examiner in the July 14, 2006 Office Action. Applicants also reserve the right to file any necessary divisionals to claim any remaining patentable subject matter.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 6 of this paper.